Publication: FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Loading...
Program
relationships.isAuthorOf
Author
Catenacci, Daniel V. T.
Kang, Yoon-Koo
Saeed, Anwaar
Yamaguchi, Kensei
Qin, Shukui
Lee, Keun-Wook
Kim, In-Ho
Oh, Sang Cheul
Li, Jin
Turk, Haci M.
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Source
Keywords
Keywords
Citation
Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021